longbridgelongbridge
  • Platform Features
    Features
    Investment ProductsPrivate Wealth ManagementTrading ToolsMarket Data ServicesAnalysis ToolsNews ServicesFor Developers
    Account Types
    For IndividualsFor Institutions
  • Café
longbridge
© 2026 Longbridge|Terms of ServicePrivacy Policy

Leerink Partners Sticks to Their Buy Rating for Ibio (IBIO)

Tip Ranks
May 15, 2026 at 03:28 PM
LongbridgeAII'm LongbridgeAI, I can summarize articles.

Leerink Partners analyst Roanna Ruiz has maintained a Buy rating on Ibio (IBIO) with a price target of $6.00. Ruiz, a 2-star analyst, has an average return of 0.6% and a 46.18% success rate. The analyst consensus for Ibio is Strong Buy, with a price target consensus of $5.80.

In a report released today, Roanna Ruiz from Leerink Partners maintained a Buy rating on Ibio, with a price target of $6.00.

Claim 55% Off TipRanks

  • Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
  • Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

According to TipRanks, Ruiz is a 2-star analyst with an average return of 0.6% and a 46.18% success rate. Ruiz covers the Healthcare sector, focusing on stocks such as Ibio, Cormedix, and Aquestive Therapeutics.

Ibio has an analyst consensus of Strong Buy, with a price target consensus of $5.80.

Login to unlock147characters for free

Due to copyright restrictions, please log in to your Longbridge account to view this content.
Thank you for your understanding and support of licensed content.

Recommended Readings

  • Apr 20, 2026 at 06:34 PMEli Lilly Announces $7 Billion Acquisition of Kelonia: Pioneering the 'In Vivo CAR-T' Frontier and Leading Gene Therapy …
  • Apr 16, 2026 at 11:12 AMUS Stocks Hit New Highs, Retail Investors Miss Out en masse: Tom Lee Says Next Rally Will Be Led by Them
  • Apr 7, 2026 at 10:32 PMReminder: Key events to watch intraday (all times Beijing Time)
  • Apr 7, 2026 at 03:50 PMGoldman Sachs Issues Rare Call: "Generational Buying Opportunity" for US Tech Stocks Has Quietly Begun
  • Apr 1, 2026 at 11:11 PMEli Lilly's Oral Weight-Loss Drug Foundayo Approved, the Only One That Can Be Taken Anytime Without Fasting

Related Stocks

iBio

iBio

USIBIO

-1.63%

Cormedix

Cormedix

USCRMD

Aquestive Therapeutic

Aquestive Therapeutic

USAQST

LongbridgeAI